Literature DB >> 21063786

EuroQol (EQ-5D) health utility scores for patients with migraine.

Ruifeng Xu1, Ralph P Insinga, Wendy Golden, X Henry Hu.   

Abstract

PURPOSE: Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity.
METHODS: We examined data for 330 20-65-year-old adults, in good physical health, who had 1-6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods.
RESULTS: The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654).
CONCLUSIONS: Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21063786     DOI: 10.1007/s11136-010-9783-5

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  37 in total

1.  US valuation of the EQ-5D health states: development and testing of the D1 valuation model.

Authors:  James W Shaw; Jeffrey A Johnson; Stephen Joel Coons
Journal:  Med Care       Date:  2005-03       Impact factor: 2.983

2.  Preference-Based EQ-5D index scores for chronic conditions in the United States.

Authors:  Patrick W Sullivan; Vahram Ghushchyan
Journal:  Med Decis Making       Date:  2006 Jul-Aug       Impact factor: 2.583

3.  Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

Authors:  A Simon Pickard; Maria C De Leon; Thomas Kohlmann; David Cella; Sarah Rosenbloom
Journal:  Med Care       Date:  2007-03       Impact factor: 2.983

4.  On the assessment of preferences for health and duration: maximal endurable time and better than dead preferences.

Authors:  Peep F M Stalmeier; Leida M Lamers; Jan J V Busschbach; Paul F M Krabbe
Journal:  Med Care       Date:  2007-09       Impact factor: 2.983

5.  Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

Authors:  R B Lipton; W F Stewart; S Diamond; M L Diamond; M Reed
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

6.  A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients.

Authors:  C R Lines; K Vandormael; W Malbecq
Journal:  Pain       Date:  2001-08       Impact factor: 6.961

Review 7.  Migraine: a review and future directions for treatment.

Authors:  M Linde
Journal:  Acta Neurol Scand       Date:  2006-08       Impact factor: 3.209

8.  Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Reto Agosti; Gianni Allais; Paul Bergmans; Gennaro Bussone; Brendan Davies; Mustafa Ertas; Michel Lanteri-Minet; Uwe Reuter; Margarita Sánchez Del Río; Jean Schoenen; Susanne Schwalen; Joop van Oene
Journal:  Lancet Neurol       Date:  2007-11-07       Impact factor: 44.182

9.  Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine.

Authors:  T W Ho; L K Mannix; X Fan; C Assaid; C Furtek; C J Jones; C R Lines; A M Rapoport
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  16 in total

Review 1.  Assessment of Quality of Life in Migraine.

Authors:  Özlem Taşkapilioğlu; Necdet Karli
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

2.  Health state utilities for migraine based on attack frequency: a time trade-off study.

Authors:  Fanni Rencz; Valentin Brodszky; Márta Péntek; Dániel Bereczki; László Gulácsi
Journal:  Neurol Sci       Date:  2014-08-10       Impact factor: 3.307

3.  EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs.

Authors:  Megan R Stafford; Asha Hareendran; Daisy S Ng-Mak; Ralph P Insinga; Ruifeng Xu; Donald E Stull
Journal:  Health Qual Life Outcomes       Date:  2012-06-12       Impact factor: 3.186

4.  Associations between demographic, disease related, and treatment pathway related variables and health related quality of life in primary care patients with coronary heart disease.

Authors:  Lena Kramer; Oliver Hirsch; Kathrin Schlössler; Susanne Träger; Erika Baum; Norbert Donner-Banzhoff
Journal:  Health Qual Life Outcomes       Date:  2012-07-09       Impact factor: 3.186

5.  Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.

Authors:  Marcello Tirani; Michela Meregaglia; Alessia Melegaro
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

6.  Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.

Authors:  Roberto Gasparini; Paolo Landa; Daniela Amicizia; Giancarlo Icardi; Walter Ricciardi; Chiara de Waure; Elena Tanfani; Paolo Bonanni; Carlo Lucioni; Angela Testi; Donatella Panatto
Journal:  Hum Vaccin Immunother       Date:  2016-05-10       Impact factor: 3.452

7.  Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.

Authors:  Anna Selivanova; Erik Buskens; Paul F M Krabbe
Journal:  Pharmacoeconomics       Date:  2018-06       Impact factor: 4.981

8.  Assessing the impact of headaches and the outcomes of treatment: A systematic review of patient-reported outcome measures (PROMs).

Authors:  Kirstie L Haywood; Tom S Mars; Rachel Potter; Shilpa Patel; Manjit Matharu; Martin Underwood
Journal:  Cephalalgia       Date:  2017-09-18       Impact factor: 6.292

9.  Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.

Authors:  Odette Reifsnider; Anuraag Kansal; Pratik Pimple; Valerie Aponte-Ribero; Sarah Brand; Sharash Shetty
Journal:  Diabetes Obes Metab       Date:  2020-12-15       Impact factor: 6.577

10.  Influence of work-related psychosocial factors on the prevalence of chronic pain and quality of life in patients with chronic pain.

Authors:  Keiko Yamada; Ko Matsudaira; Hironori Imano; Akihiko Kitamura; Hiroyasu Iso
Journal:  BMJ Open       Date:  2016-04-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.